HARVARD BIOSCIENCE INC
About HARVARD BIOSCIENCE INC
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $86.5M
- Net income
- -$56.7M
- Total assets
- $80.1M
- Market cap
- $27.9M
- Gross margin
- 57.7%
- Operating margin
- -56.1%
- Net margin
- -65.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $86.5M
- Cost of revenue
- $36.6M
- Gross profit
- $49.9M
- Operating expenses
- $98.5M
- Operating income
- -$48.6M
- Income tax
- -$686.0K
- Net income
- -$56.7M
- EPS (basic)
- $-1.28
- EPS (diluted)
- $-1.28
Balance sheet
- Total assets
- $80.1M
- Current assets
- $48.2M
- Total liabilities
- $66.3M
- Current liabilities
- $22.0M
- Shareholders’ equity
- $13.7M
Cash flow
- Operating cash flow
- $6.7M
- Investing cash flow
- -$1.9M
- Financing cash flow
- -$1.3M
- Net cash flow
- $3.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $27.9M
- EPS (diluted)
- $-1.28
- Shares outstanding
- 4.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 7, 2000
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $56.7M in FY2025.
- Revenue declined 27% from FY2021 to FY2025.
- Gross margin of 57.7%, net margin -65.5%.
- Trading 24% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review HARVARD BIOSCIENCE INC.
Write a review
News about HARVARD BIOSCIENCE INC
News & sentiment via Polygon.io
